Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAV in Patients Needing Vascular Access for Dialysis
NCT04135417Phase 2Completed
- Sponsor
- Humacyte
- Start
- Nov 2019
- Primary completion
- May 2021
- Modality
- Device-based Delivery, Tissue Cells, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acellular tissue engineered vessel in chronic kidney disease (CKD), sponsored by Humacyte. Primary endpoints: Cumulative Number of Subjects With Adverse Events Indicating Possible Mechanical Failure or Weakness of the HAV at 3 months, Number of Participants With Baseline Change of Panel Reactive Antibody (PRA) Value at 2 months and 2 more. Started Nov 2019; status: completed.
02
Drugs
acellular tissue engineered vessel
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04135417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04135417.